Prosecution Insights
Last updated: April 19, 2026
Application No. 17/651,439

OXADIAZOLES FOR USE IN CONTROLLING PHYTOPATHOGENIC FUNGI

Non-Final OA §112§DP
Filed
Feb 17, 2022
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pi Industries Ltd.
OA Round
2 (Non-Final)
78%
Grant Probability
Favorable
2-3
OA Rounds
2y 5m
To Grant
74%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
1410 granted / 1810 resolved
+17.9% vs TC avg
Minimal -3% lift
Without
With
+-3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
29 currently pending
Career history
1839
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
7.1%
-32.9% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
52.2%
+12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1810 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 17-29 are currently pending in the instant application. Applicants have amended claim 17 and canceled claim 33 in an amendment filed on November 12, 2025. Claim 29 is rejected, claim 17 is objected and claims 18-28 are considered to be allowable in this Office Action. I. Response to Arguments/Remarks Applicants’ amendment, filed on November 12, 2025, has overcome the rejection of claims 17-28 under 35 USC 112(b) as being indefinite for the definition of variable L1 and the rejection of claims 17-28 under 35 USC 112(b) as being indefinite for the limitation of variable R1 referring to Formula I which lacks antecedent basis. The above rejections have been withdrawn. Claims 17-28 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claim 29, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, is hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because a claimed invention previously withdrawn from consideration under 37 CFR 1.142 has been rejoined, the restriction requirement between groups II and III as set forth in the Office action mailed on March 6, 2025 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. II. Rejection(s) Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 29 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 29 recites the limitation “reacting the compound of formula Ia” which is dependent on claim 17 but “a compound of formula Ia” is not found in claim 17. Claim 17 is only drawn to a compound of formula Ib. There is insufficient antecedent basis for this limitation in the claim. Applicants are suggested to amend claim 29 so that the limitation “reacting the compound of formula Ia” now reads “reacting a compound of formula Ia” to overcome the rejection. III. Objections Claim Objections Claim 17 is objected to because of the following informalities: the limitation “or N-oxides, metal complexes, isomers, polymorphs or the agriculturally acceptable salts thereof” should now read “or an N-oxide, metal complex, isomer, polymorph or an agriculturally acceptable salt thereof”. IV. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is (571)272-9043. The examiner can normally be reached on M-F 7AM-4PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached on (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Feb 17, 2022
Application Filed
Aug 09, 2025
Non-Final Rejection — §112, §DP
Nov 12, 2025
Response Filed
Mar 14, 2026
Non-Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600903
DELAYED FLUORESCENCE COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594265
METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3
2y 5m to grant Granted Apr 07, 2026
Patent 12595231
NOVEL CRYSTALLINE SALT FORMS OF MESEMBRINE
2y 5m to grant Granted Apr 07, 2026
Patent 12590047
METHOD FOR PRODUCING FLUORINE-CONTAINING OLEFIN
2y 5m to grant Granted Mar 31, 2026
Patent 12583818
NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
78%
Grant Probability
74%
With Interview (-3.4%)
2y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 1810 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month